Brief: Can-Fite Reports First Quarter 2022 Financial Results & Provides Clinical Update
26/05/2022 12:05
May 26 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS &
PROVIDES
CLINICAL UPDATE
* CAN FITE BIOPHARMA LTD - QTRLY REVENUES $205,000 VERSUS
$148,000
* CAN FITE BIOPHARMA LTD - QTRLY LOSS PER SHARE $0.00
Source text for Eikon: ID:nBw5TRP9ga
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage